Handel Inozyme Pharma, Inc. - INZY CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Handelsbetingelser
| Spænd | - | ||||||||
|
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.024068% | ||||||||
|
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.001846% | ||||||||
| Gebyr natten over, tid | 21:00 (UTC) | ||||||||
| Min. handlet mængde | 1 | ||||||||
| Valuta | USD | ||||||||
| Margen | 20% | ||||||||
| Aktiebørs | United States of America | ||||||||
| Kommission på handel | 0% |
*Information provided by Capital.com
Nøglestatistikker
| Tidligere luk* | N/A |
| Åben* | N/A |
| 1-Års Ændring* | N/A |
| Dagens Spænd* | N/A |
| 52-Ugers Spænd | 0.99-6.25 |
| Gennemsnitlig Volumen (10 dage) | 716.27K |
| Gennemsnitlig Volumen (3 måneder) | 29.04M |
| Market Cap | 111.49M |
| P/E-forhold | -100.00K |
| Udestående aktier | 40.39M |
| Omsætning | N/A |
| EPS | -2.26 |
| Dividend (Udbytte %) | N/A |
| Beta | -100.00K |
| Næste indtjeningsopgørelse | Mar 22, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Luk | Change | Change (%) | Åben | High | Low |
|---|
Inozyme Pharma, Inc. Events
| Tid (UTC) (UTC) | Land | Begivenhed |
|---|---|---|
| No events scheduled | ||
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 |
| Totale Driftsudgifter | 56.646 | 57.041 | 20.806 | 11.593 |
| Salgs/Generelle/Admin. Udgifter, Total | 18.926 | 10.548 | 4.586 | 3.494 |
| Forskning & Udvikling | 37.72 | 46.493 | 16.22 | 8.099 |
| Driftsindtægter | -56.646 | -57.041 | -20.806 | -11.593 |
| Renteindkomst (Udgift), Netto Ikke-Drift | 0.211 | 0.37 | 1.106 | 0.284 |
| Andre, Netto | -0.189 | 0.247 | -0.024 | 4.345 |
| Netto Indkomst Før Skat | -56.624 | -56.424 | -19.724 | -6.964 |
| Netto Indkomst Efter Skat | -56.624 | -56.424 | -19.724 | -6.964 |
| Netto Indkomst Før Ekstra Ting | -56.624 | -56.424 | -19.724 | -6.964 |
| Netto Indkomst | -56.624 | -56.424 | -19.724 | -6.964 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -56.624 | -56.424 | -19.724 | -6.964 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -56.624 | -56.424 | -19.724 | -6.964 |
| Fortyndet Netto Indkomst | -56.624 | -56.424 | -19.724 | -6.964 |
| Fortyndet Vægtet Gennemsnit Aktier | 23.5583 | 11.0365 | 20.3148 | 20.3148 |
| Fortyndet EPS Uden Ekstraordinære Ting | -2.40357 | -5.11249 | -0.97092 | -0.3428 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
| Fortyndet Normaliseret EPS | -2.40357 | -5.11249 | -0.97092 | -0.3428 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 | 0 |
| Totale Driftsudgifter | 16.839 | 18.757 | 14.262 | 12.655 | 10.972 |
| Salgs/Generelle/Admin. Udgifter, Total | 5.025 | 5.206 | 4.916 | 4.435 | 4.369 |
| Forskning & Udvikling | 11.814 | 13.551 | 9.346 | 8.22 | 6.603 |
| Driftsindtægter | -16.839 | -18.757 | -14.262 | -12.655 | -10.972 |
| Renteindkomst (Udgift), Netto Ikke-Drift | 0.06 | 0.043 | 0.047 | 0.058 | 0.063 |
| Andre, Netto | -0.105 | -0.04 | -0.065 | 0.057 | -0.141 |
| Netto Indkomst Før Skat | -16.884 | -18.754 | -14.28 | -12.54 | -11.05 |
| Netto Indkomst Efter Skat | -16.884 | -18.754 | -14.28 | -12.54 | -11.05 |
| Netto Indkomst Før Ekstra Ting | -16.884 | -18.754 | -14.28 | -12.54 | -11.05 |
| Netto Indkomst | -16.884 | -18.754 | -14.28 | -12.54 | -11.05 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -16.884 | -18.754 | -14.28 | -12.54 | -11.05 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -16.884 | -18.754 | -14.28 | -12.54 | -11.05 |
| Fortyndet Netto Indkomst | -16.884 | -18.754 | -14.28 | -12.54 | -11.05 |
| Fortyndet Vægtet Gennemsnit Aktier | 23.6863 | 23.6673 | 23.6435 | 23.4906 | 23.4295 |
| Fortyndet EPS Uden Ekstraordinære Ting | -0.71282 | -0.7924 | -0.60397 | -0.53383 | -0.47163 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Fortyndet Normaliseret EPS | -0.71282 | -0.7924 | -0.60397 | -0.53383 | -0.47163 |
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Totale Nuværende Aktiver | 115.342 | 150.979 | 47.46 | 43.267 |
| Likvider og Kortsigtede Investeringer | 111.801 | 147.697 | 47.132 | 43.163 |
| Likvider & Lignende | 23.316 | 28.04 | 31.605 | 35.966 |
| Kortsigtede Investeringer | 88.485 | 119.657 | 15.527 | 7.197 |
| Totale Tilgodehavender, Netto | 0.062 | 0.155 | 0.104 | 0.031 |
| Prepaid Expenses | 3.479 | 3.127 | 0.224 | 0.073 |
| Total Assets | 123.541 | 169.363 | 47.944 | 43.543 |
| Property/Plant/Equipment, Total - Net | 4.436 | 2.648 | 0.298 | 0.242 |
| Property/Plant/Equipment, Total - Gross | 5.437 | 2.975 | 0.408 | 0.269 |
| Accumulated Depreciation, Total | -1.001 | -0.327 | -0.11 | -0.027 |
| Other Long Term Assets, Total | 3.763 | 3.537 | 0.186 | 0.034 |
| Total Current Liabilities | 11.633 | 9.973 | 3.236 | 2.389 |
| Accounts Payable | 2.394 | 3.069 | 0.901 | 0.984 |
| Accrued Expenses | 9.239 | 6.625 | 2.335 | 1.405 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
| Total Liabilities | 14.273 | 11.26 | 3.236 | 2.389 |
| Total Long Term Debt | 0 | 0 | 0 | 0 |
| Total Equity | 109.268 | 158.103 | 44.708 | 41.154 |
| Preferred Stock - Non Redeemable, Net | 77.927 | 55.029 | ||
| Common Stock | 0.002 | 0.002 | 0.001 | 0.001 |
| Additional Paid-In Capital | 256.948 | 249.175 | 1.427 | 1.054 |
| Retained Earnings (Accumulated Deficit) | -147.7 | -91.076 | -34.652 | -14.928 |
| Other Equity, Total | 0.018 | 0.002 | 0.005 | -0.002 |
| Total Liabilities & Shareholders’ Equity | 123.541 | 169.363 | 47.944 | 43.543 |
| Total Common Shares Outstanding | 23.6726 | 23.385 | 20.3148 | 20.3148 |
| Total Preferred Shares Outstanding | 72.4164 | |||
| Long Term Investments | 0 | 12.199 | ||
| Other Current Liabilities, Total | 0 | 0.279 | ||
| Other Liabilities, Total | 2.64 | 1.287 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 100.583 | 115.342 | 130.579 | 140.962 | 148.041 |
| Likvider og Kortsigtede Investeringer | 97.773 | 111.801 | 125.283 | 137.464 | 145.086 |
| Likvider & Lignende | 31.943 | 23.316 | 27.229 | 26.239 | 16.486 |
| Kortsigtede Investeringer | 65.83 | 88.485 | 98.054 | 111.225 | 128.6 |
| Totale Tilgodehavender, Netto | 0.048 | 0.062 | 0.073 | 0.095 | 0.122 |
| Prepaid Expenses | 2.762 | 3.479 | 5.223 | 3.403 | 2.833 |
| Total Assets | 108.931 | 123.541 | 137.746 | 148.259 | 158.915 |
| Property/Plant/Equipment, Total - Net | 4.184 | 4.436 | 4.743 | 4.859 | 5.029 |
| Property/Plant/Equipment, Total - Gross | 5.363 | 5.437 | 5.562 | 5.511 | 5.514 |
| Accumulated Depreciation, Total | -1.179 | -1.001 | -0.819 | -0.652 | -0.485 |
| Long Term Investments | 0 | 0 | 0 | 2.548 | |
| Other Long Term Assets, Total | 4.164 | 3.763 | 2.424 | 2.438 | 3.297 |
| Total Current Liabilities | 12.26 | 11.633 | 8.943 | 6.972 | 6.832 |
| Accounts Payable | 2.2 | 2.394 | 0.626 | 0.796 | 1.709 |
| Accrued Expenses | 10.06 | 9.239 | 8.317 | 6.176 | 5.123 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 14.702 | 14.273 | 11.772 | 9.985 | 10.026 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 2.442 | 2.64 | 2.829 | 3.013 | 3.194 |
| Total Equity | 94.229 | 109.268 | 125.974 | 138.274 | 148.889 |
| Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
| Additional Paid-In Capital | 258.94 | 256.948 | 254.915 | 252.92 | 251.001 |
| Retained Earnings (Accumulated Deficit) | -164.584 | -147.7 | -128.946 | -114.666 | -102.126 |
| Other Equity, Total | -0.129 | 0.018 | 0.003 | 0.018 | 0.012 |
| Total Liabilities & Shareholders’ Equity | 108.931 | 123.541 | 137.746 | 148.259 | 158.915 |
| Total Common Shares Outstanding | 23.8184 | 23.6726 | 23.6647 | 23.5706 | 23.4737 |
| Other Current Liabilities, Total | 0 | 0 | 0 | ||
| Preferred Stock - Non Redeemable, Net | 0 | 0 |
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Netto indkomst/Startlinje | -56.624 | -56.424 | -19.724 | -6.964 |
| Likvider Fra Driftsaktiviteter | -48.153 | -35.974 | -18.81 | -9.437 |
| Likvider Fra Driftsaktiviteter | 0.674 | 0.217 | 0.083 | 0.026 |
| Ikke-Likvide Ting | 7.712 | 20.344 | 0.23 | -3.93 |
| Ændringer i Driftskapital | 0.085 | -0.111 | 0.601 | 1.431 |
| Likvider fra Investeringsaktiviteter | 42.796 | -117.179 | -8.391 | 9.006 |
| Kapitaludgifter | -0.397 | -0.568 | -0.139 | -0.259 |
| Andre Investerings-Cash-Flow-Ting, Total | 43.193 | -116.611 | -8.252 | 9.265 |
| Likvider fra Financieringsaktiviteter | 0.609 | 149.812 | 22.97 | 31.945 |
| Udstedelse (Pensionering) af Aktier, Netto | 0.609 | 149.812 | 22.97 | 31.945 |
| Netto Ændring i Likviditet | -4.724 | -3.341 | -4.231 | 31.514 |
| Udenlandsk Børs Effekter | 0.024 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -16.884 | -56.624 | -37.87 | -23.59 | -11.05 |
| Cash From Operating Activities | -14.16 | -48.153 | -34.709 | -22.409 | -12.376 |
| Cash From Operating Activities | 0.178 | 0.674 | 0.492 | 0.325 | 0.158 |
| Non-Cash Items | 1.779 | 7.712 | 5.567 | 3.689 | 1.725 |
| Changes in Working Capital | 0.767 | 0.085 | -2.898 | -2.833 | -3.209 |
| Cash From Investing Activities | 22.562 | 42.796 | 33.309 | 20.247 | 0.573 |
| Capital Expenditures | -0.017 | -0.397 | -0.357 | -0.278 | -0.088 |
| Other Investing Cash Flow Items, Total | 22.579 | 43.193 | 33.666 | 20.525 | 0.661 |
| Cash From Financing Activities | 0.24 | 0.609 | 0.598 | 0.361 | 0.249 |
| Issuance (Retirement) of Stock, Net | 0.24 | 0.609 | 0.598 | 0.361 | 0.249 |
| Net Change in Cash | 8.627 | -4.724 | -0.811 | -1.801 | -11.554 |
| Foreign Exchange Effects | -0.015 | 0.024 | -0.009 |
| Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
|---|---|---|---|---|---|---|
| Longitude Capital Management Co., LLC | Venture Capital | 10.3341 | 4174379 | 1355000 | 2022-04-19 | LOW |
| Sofinnova Investments, Inc | Venture Capital | 9.0491 | 3655308 | 0 | 2022-12-31 | MED |
| Deep Track Capital LP | Hedge Fund | 8.0457 | 3250000 | 0 | 2022-12-31 | MED |
| Adage Capital Management, L.P. | Hedge Fund | 7.6747 | 3100138 | 503466 | 2022-12-31 | LOW |
| Rock Springs Capital Management LP | Hedge Fund | 7.6397 | 3086027 | 278409 | 2022-12-31 | LOW |
| VR Adviser, LLC | Venture Capital | 6.7088 | 2709987 | 0 | 2022-12-31 | MED |
| Pivotal Bioventure Partners Investment Advisor LLC | Investment Advisor | 6.5879 | 2661154 | 0 | 2022-12-31 | LOW |
| New Enterprise Associates (NEA) | Venture Capital | 6.0347 | 2437689 | -6690 | 2022-12-31 | LOW |
| Cowen Investment Management LLC | Investment Advisor/Hedge Fund | 5.4584 | 2204876 | 208599 | 2022-12-31 | MED |
| Sphera Funds Management Ltd. | Hedge Fund | 5.1895 | 2096258 | 471200 | 2023-03-03 | HIGH |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.3263 | 1343622 | 559 | 2022-12-31 | LOW |
| Affinity Asset Advisors LLC | Hedge Fund | 1.2378 | 500000 | 500000 | 2022-12-31 | HIGH |
| Millennium Management LLC | Hedge Fund | 0.7376 | 297936 | 127752 | 2022-12-31 | HIGH |
| Laurion Capital Management LP | Hedge Fund | 0.6729 | 271800 | 0 | 2022-12-31 | HIGH |
| Bolte (Axel) | Individual Investor | 0.6483 | 261890 | 3315 | 2022-09-30 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.6409 | 258900 | 103500 | 2022-12-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.6362 | 256970 | -1351 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5771 | 233126 | -559 | 2022-12-31 | LOW |
| BioImpact Capital LLC | Investment Advisor/Hedge Fund | 0.5706 | 230500 | -430644 | 2022-12-31 | LOW |
| Overbrook Management Corporation | Investment Advisor | 0.543 | 219326 | 150000 | 2022-12-31 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group500K+
Handlende
92K+
Månedlkige, aktive klienter
$53M+
Månedlig investeringsvolumen
$30M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
Handelskurtage
0
- 1:1
Gearing
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben
Luk
Short Long
Inozyme Pharma, Inc. Company profile
Om Inozyme Pharma, Inc.
Inozyme Pharma, Inc. er en biofarmaceutisk virksomhed i den kliniske fase for sjældne sygdomme. Virksomheden fokuserer på at udvikle terapier til behandling af sygdomme med unormal mineralisering, der påvirker blodkar, blødt væv og skelet. Virksomheden fokuserer også på at udvikle en terapi til behandling af de sjældne genetiske sygdomme Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) og ATP-binding cassette sub-family C member 6 (ABCC6) mangler. Selskabets vigtigste produktkandidat, INZ-701, er et opløseligt, rekombinant eller genetisk manipuleret fusionsprotein, der er designet til at korrigere en defekt i mineraliseringsvejen forårsaget af ENPP1- og ABCC6-mangler.
| Industry: | Biotechnology & Medical Research (NEC) |
321 Summer Street
Suite 400
02210
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com